603566.SH
Pulike Biological Engineering, Inc.
SSE · Healthcare · Biotechnology · CN
CNY 9.19
−1.92%Year over year
Reported trailing growth
- Revenue
- -2.3%
- EBITDA
- —
- EBIT
- +47.6%
- EPS
- +45.7%
- Free cash flow
- -19.0%
- Operating cash flow
- -14.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.0%
- EBITDA
- +9.4%
- EBIT
- +5.3%
- Net income
- +3.3%
- EPS
- +1.3%
- Free cash flow
- +90.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026